This showed that the wild-type peptide but not its mutant dose-dependently repressed ER transcriptional activity in the ER+ (MCF-7) breast cancer cells, indicating the potential of this peptide as an ER antagonist (Figure 3C–F). Here, ESR1 is linked to breast cancer.